LOXO-195 is currently under evaluation in a phase I/II trial (NCT03215511) enrolling patients with NTRK-rearranged tumors—including thyroid cancer—previously treated with a TRK inhibitor. This evidence concerns the gene NTRK1 and thyroid gland carcinoma.